Literature DB >> 20711717

Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study.

H C Gerstein1, S Islam, S Anand, W Almahmeed, A Damasceno, A Dans, C C Lang, M A Luna, M McQueen, S Rangarajan, A Rosengren, X Wang, S Yusuf.   

Abstract

AIMS/HYPOTHESIS: Although diabetes is an established risk factor for myocardial infarction (MI), disease control may vary. HbA(1c) is a reliable index of ambient glucose levels and may provide more information on MI risk than diabetes status.
METHODS: The relationship between HbA(1c) levels in MI patients and controls who participated in the 52 country INTERHEART study was analysed.
RESULTS: In 15,780 participants with a HbA(1c) value (1,993 of whom had diabetes), the mean (SD) levels for HbA(1c) were 6.15% (1.10) in the 6,761 MI patients and 5.85% (0.80) in the control participants. After adjustment for age, sex and nine major MI risk factors (including diabetes), higher HbA(1c) fifths above the lowest fifth (HbA(1c) <5.4%) were associated with progressively higher OR of MI, with OR for the highest HbA(1c) fifth (≥ 6.12%) being 1.55 (95% CI 1.37-1.75). When analysed as a continuous variable after adjustment for the same factors, every 1% higher HbA(1c) value was associated with 19% (95% CI 14-23) higher odds of MI, while every 0.5% higher HbA(1c) was associated with 9% higher odds of MI (95% CI 7-11). Concordant relationships were noted across subgroups, with a higher OR noted in younger people, patients without diabetes or hypertension, and those from some regions and ethnicities. CONCLUSIONS/
INTERPRETATION: The HbA(1c) value provides more information on MI odds than self-reported diabetes status or many other established risk factors. Every 1% increment independently predicts a 19% higher odds of MI after accounting for other MI risk factors including diabetes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20711717     DOI: 10.1007/s00125-010-1871-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study.

Authors:  Elizabeth Selvin; Josef Coresh; Sherita H Golden; Frederick L Brancati; Aaron R Folsom; Michael W Steffes
Journal:  Arch Intern Med       Date:  2005-09-12

2.  Glycosal: the first rapid, point-of-care test for the determination of hemoglobin A1c in patients with diabetes.

Authors:  T Stevenson
Journal:  Diabetes Technol Ther       Date:  1999       Impact factor: 6.118

3.  Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.

Authors:  Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

4.  Blood glucose and risk of cardiovascular disease in the Asia Pacific region.

Authors:  C M M Lawes; V Parag; D A Bennett; I Suh; T H Lam; G Whitlock; F Barzi; M Woodward
Journal:  Diabetes Care       Date:  2004-12       Impact factor: 19.112

Review 5.  Is it possible to reduce cardiovascular risk with glucose-lowering approaches?

Authors:  Hertzel C Gerstein
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

6.  Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.

Authors:  Anna Norhammar; Ake Tenerz; Göran Nilsson; Anders Hamsten; Suad Efendíc; Lars Rydén; Klas Malmberg
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

7.  Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

Authors:  Robert M Califf; Mitradev Boolell; Steven M Haffner; M Angelyn Bethel; John McMurray; Anil Duggal; Rury R Holman
Journal:  Am Heart J       Date:  2008-10       Impact factor: 4.749

8.  Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study.

Authors:  Annika Rosengren; Steven Hawken; Stephanie Ounpuu; Karen Sliwa; Mohammad Zubaid; Wael A Almahmeed; Kathleen Ngu Blackett; Chitr Sitthi-amorn; Hiroshi Sato; Salim Yusuf
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

9.  Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).

Authors:  Hertzel Gerstein; Salim Yusuf; Matthew C Riddle; Lars Ryden; Jackie Bosch
Journal:  Am Heart J       Date:  2007-11-26       Impact factor: 4.749

10.  Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study.

Authors:  Eric J Brunner; Martin J Shipley; Daniel R Witte; John H Fuller; Michael G Marmot
Journal:  Diabetes Care       Date:  2006-01       Impact factor: 19.112

View more
  16 in total

1.  HbA1c: a useful cardiovascular risk marker in those without diabetes?

Authors:  D Preiss; N Sattar
Journal:  Diabetologia       Date:  2010-09-11       Impact factor: 10.122

2.  Dysglycaemia, dyslipidaemia and hypertension: risk factors primarily focused on the disease or risk estimates primarily focused on the patient?

Authors:  H C Gerstein
Journal:  Diabetologia       Date:  2010-11-20       Impact factor: 10.122

3.  Trends in prevalence of diabetes in Asian countries.

Authors:  Ambady Ramachandran; Chamukuttan Snehalatha; Ananth Samith Shetty; Arun Nanditha
Journal:  World J Diabetes       Date:  2012-06-15

Review 4.  Prediabetes and associated disorders.

Authors:  Martin Buysschaert; José Luís Medina; Michael Bergman; Avni Shah; Jaqueline Lonier
Journal:  Endocrine       Date:  2014-10-08       Impact factor: 3.633

Review 5.  Cardiovascular risk stratification and management in pre-diabetes.

Authors:  Kristine Færch; Dorte Vistisen; Nanna Borup Johansen; Marit Eika Jørgensen
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

Review 6.  Type 2 diabetes and cardiovascular disease in women.

Authors:  A Norhammar; K Schenck-Gustafsson
Journal:  Diabetologia       Date:  2012-09-04       Impact factor: 10.122

7.  Associations Between Prediabetes, by Three Different Diagnostic Criteria, and Incident CVD Differ in South Asians and Europeans.

Authors:  Sophie V Eastwood; Therese Tillin; Naveed Sattar; Nita G Forouhi; Alun D Hughes; Nish Chaturvedi
Journal:  Diabetes Care       Date:  2015-10-20       Impact factor: 19.112

8.  Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial.

Authors: 
Journal:  Diabetes Care       Date:  2013-05-08       Impact factor: 19.112

9.  Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE).

Authors:  Eva M Lonn; Jackie Bosch; Rafael Diaz; Patricio Lopez-Jaramillo; Ambady Ramachandran; Nicolae Hâncu; Markolf Hanefeld; Henry Krum; Lars Ryden; Sandra Smith; Matthew J McQueen; Leanne Dyal; Salim Yusuf; Hertzel C Gerstein
Journal:  Diabetes Care       Date:  2013-04-05       Impact factor: 19.112

Review 10.  Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.

Authors:  Caroline S Fox; Sherita Hill Golden; Cheryl Anderson; George A Bray; Lora E Burke; Ian H de Boer; Prakash Deedwania; Robert H Eckel; Abby G Ershow; Judith Fradkin; Silvio E Inzucchi; Mikhail Kosiborod; Robert G Nelson; Mahesh J Patel; Michael Pignone; Laurie Quinn; Philip R Schauer; Elizabeth Selvin; Dorothea K Vafiadis
Journal:  Diabetes Care       Date:  2015-08-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.